Vascular Dementia - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Vascular Dementia – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Vascular Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Vascular Dementia: Overview
Vascular dementia (VaD) is one of the most common causes of dementia after Alzheimer’s disease, causing around 15% of cases. Vascular dementia may result not only from large-vessel strokes (multi-infarct dementia) but also from ischemic lesions caused by small-vessel pathology, including lacunar strokes and incomplete white matter ischemia (subcortical ischemic vascular dementia), as well as from hypoperfusion caused by heart disease or circulatory disturbances. Cognitive changes in vascular dementia are much more variable than in other disorders such as Alzheimer’s disease, and are highly dependent on the particular neural substrates affected by the vascular pathology. Some symptoms may be similar to those of other types of dementia. Memory loss is common in the early stages of Alzheimer's, but is not usually the main early symptom of vascular dementia. Vascular dementia is caused by reduced blood supply to the brain due to diseased blood vessels. To be healthy and function properly, brain cells need a constant supply of blood to bring oxygen and nutrients. Blood is delivered to the brain through a network of vessels called the vascular system. If the vascular system within the brain becomes damaged - so that the blood vessels leak or become blocked - then blood cannot reach the brain cells and they will eventually die. There is currently no cure for vascular dementia: the brain damage that causes it cannot be reversed. However, there is a lot that can be done to enable someone to live well with the condition. This will involve drug and non-drug treatment, support and activities.
'Vascular Dementia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Dementia pipeline landscape is provided which includes the disease overview and Vascular Dementia treatment guidelines. The assessment part of the report embraces, in depth Vascular Dementia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Dementia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Vascular Dementia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vascular Dementia Emerging Drugs
Further product details are provided in the repor
Vascular Dementia: Therapeutic Assessment
This segment of the report provides insights about the different Vascular Dementia drugs segregated based on following parameters that define the scope of the report, such as:
Vascular Dementia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vascular Dementia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Dementia drugs.
Vascular Dementia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Vascular Dementia – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Vascular Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Vascular Dementia: Overview
Vascular dementia (VaD) is one of the most common causes of dementia after Alzheimer’s disease, causing around 15% of cases. Vascular dementia may result not only from large-vessel strokes (multi-infarct dementia) but also from ischemic lesions caused by small-vessel pathology, including lacunar strokes and incomplete white matter ischemia (subcortical ischemic vascular dementia), as well as from hypoperfusion caused by heart disease or circulatory disturbances. Cognitive changes in vascular dementia are much more variable than in other disorders such as Alzheimer’s disease, and are highly dependent on the particular neural substrates affected by the vascular pathology. Some symptoms may be similar to those of other types of dementia. Memory loss is common in the early stages of Alzheimer's, but is not usually the main early symptom of vascular dementia. Vascular dementia is caused by reduced blood supply to the brain due to diseased blood vessels. To be healthy and function properly, brain cells need a constant supply of blood to bring oxygen and nutrients. Blood is delivered to the brain through a network of vessels called the vascular system. If the vascular system within the brain becomes damaged - so that the blood vessels leak or become blocked - then blood cannot reach the brain cells and they will eventually die. There is currently no cure for vascular dementia: the brain damage that causes it cannot be reversed. However, there is a lot that can be done to enable someone to live well with the condition. This will involve drug and non-drug treatment, support and activities.
'Vascular Dementia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Dementia pipeline landscape is provided which includes the disease overview and Vascular Dementia treatment guidelines. The assessment part of the report embraces, in depth Vascular Dementia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Dementia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Dementia R&D. The therapies under development are focused on novel approaches to treat/improve Vascular Dementia.
This segment of the Vascular Dementia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vascular Dementia Emerging Drugs
- Akatinol Memantine: Merz Pharma
- Butylphthalide soft capsules: CSPC Ouyi Pharmaceutical
Further product details are provided in the repor
Vascular Dementia: Therapeutic Assessment
This segment of the report provides insights about the different Vascular Dementia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Vascular Dementia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Vascular Dementia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vascular Dementia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Dementia drugs.
Vascular Dementia Report Insights
- Vascular Dementia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Vascular Dementia drugs?
- How many Vascular Dementia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular Dementia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vascular Dementia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vascular Dementia and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Vascular Dementia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Vascular Dementia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Vascular Dementia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Vascular Dementia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Akatinol Memantine: Merz Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
CY6463: Cyclerion therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
Comparative Analysis
AR1001: AriBio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Vascular Dementia Key Companies
Vascular Dementia Key Products
Vascular Dementia- Unmet Needs
Vascular Dementia- Market Drivers and Barriers
Vascular Dementia- Future Perspectives and Conclusion
Vascular Dementia Analyst Views
Vascular Dementia Key Companies
Appendix
Executive Summary
Vascular Dementia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Vascular Dementia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Vascular Dementia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Vascular Dementia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Akatinol Memantine: Merz Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
CY6463: Cyclerion therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
Comparative Analysis
AR1001: AriBio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Vascular Dementia Key Companies
Vascular Dementia Key Products
Vascular Dementia- Unmet Needs
Vascular Dementia- Market Drivers and Barriers
Vascular Dementia- Future Perspectives and Conclusion
Vascular Dementia Analyst Views
Vascular Dementia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Vascular Dementia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Vascular Dementia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Vascular Dementia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Vascular Dementia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
